SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.
Search results for: health insurance
Fight for Change: 2 ARP Members on Why Advocacy Is Important to Them
Two ARP members who currently serve on the ACR Government Affairs Committee discuss why & how they got involved in advocacy.
Talking to Patients About Medicare Choices: Q&A with the Arthritis Foundation’s Nick Turkas, MS
Access to care is critical for treating arthritis and other chronic rheumatic conditions. That’s why choosing the best Medicare plan fit is such an important decision. Use these tips from the Arthritis Foundation’s Nick Turkas, MS, to help your patients make their best choice for insurance coverage.
Charting a New Course Post-PHE
The public health emergency (PHE), in place since 2020, officially expired at midnight on May 11. The PHE declaration allowed significant flexibility in the healthcare system. The end of the PHE impacts several policies, including changes in Medicare and Medicaid policies. What do these changes mean for providers?
Large Language Models in Medicine: The potential to reduce workloads, leverage the EMR for better communication & more
Large language models are a type of AI that allows users to generate new content, drawing from a huge dataset to learn how to mimic “natural language” with many possible beneficial applications for this technology in medicine.
JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
The Only Rheumatologist on the Island
“What are you up to this weekend?” “Flying to Guam.” “What? Why?” “I promised an entire island I’d be their doctor.” In fall 2021, Jonathon Thorp, MD, phoned a friend. A passionate internist, he was bound and determined to bring a rheumatologist to Guam. Unlike most primary care providers (PCPs), he was willing to prescribe…
Mark Cuban: Mixing Up the Pharmaceutical Landscape
The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…
Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw
A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.
Speak Out Rheum: To Prescribe Is Humane (Unless You’re In Texas)
You are a rheumatologist in Texas. You are very well trained. Your mentors included some of the leaders in rheumatology, and you are respected by your colleagues and your patients. You know the devastation of untreated rheumatoid arthritis and lupus. A young woman with recent onset of systemic lupus erythematosus is your new patient. You…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 115
- Next Page »